1-2 of 2
Charlotte Hansen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Free
María-Victoria Mateos, Nizar Bahlis, Aurore Perrot, Ajay Nooka, Jin Lu, Charlotte Pawlyn, Roberto Mina, Gaston Caeiro, Alain Kentos, Vania Hungria, Donna Reece, Ting Niu, Anne Mylin, Charlotte Hansen, Raphael Teipel, Britta Besemer, Meletios Dimopoulos, Elena Zamagni, Satoshi Yoshihara, Kihyun Kim, Chang-Ki Min, Paulus Geerts, Elena Van Leeuwen-Segarceanu, Agata Tyczynska, Juan Luis Reguera, Magnus Johansson, Markus Hansson, Mehmet Turgut, Mark Grey, Surbhi Sidana, Paula Rodriguez-Otero, Joaquin Martinez-Lopez, Hamza Hashmi, Robin Carson, Rachel Kobos, Weili Sun, Kristen Lantz, Anne Seifert, Debbie Briseno-Toomey, Lisa O'Rourke, Maria Rubin, Diego Vieyra, Lijuan Kang, Luciano Costa
Journal: Blood
Blood (2025) 146 (Supplement 2): LBA-6.
https://doi.org/10.1182/blood-2025-LBA-6
Published: 2025
Journal Articles

Real-world use, safety, and efficacy of teclistamab with or without prophylactic tocilizumab in relapsed/refractory multiple myeloma; Results from the danish ABCD study.

Free
Astrid Hundeboell Torpe, Jonathan Thorsen, Katrine Fladeland Iversen, Sarah Leeth Farmer, Thomas Lund, Charlotte Hansen, Lene Kongsgaard Nielsen, Nicolai Grønne Dahlager Jørgensen, Maja Vase, Elena Manuela Teodorescu, Gustav Mathiasen, Morten Salomo, Christina Wennerstöm, Agoston Szabo
Journal: Blood
Blood (2025) 146 (Supplement 1): 718.
https://doi.org/10.1182/blood-2025-718
Published: 2025